Treatment of Ileal Ulcers

Introduction to Treatment Options

The European Society of Gastrointestinal Endoscopy recommends that treatment for ileal ulcers should be tailored to the severity of disease, with options including high-dose mesalazine for mild disease, corticosteroids for moderate to severe disease, or surgery for refractory cases 1, 2

For patients with mild ileocolonic Crohn's disease, high-dose mesalazine (4g daily) may be sufficient as initial therapy, according to the European Crohn’s and Colitis Organisation 1
Patient preferences should be considered when selecting therapy, as this impacts adherence and outcomes, as suggested by the European Society of Gastrointestinal Endoscopy 1

The British Society of Gastroenterology recommends oral corticosteroids such as prednisolone 40 mg daily for patients with moderate to severe disease, or those with mild to moderate disease that has failed to respond to mesalazine 1, 2
Prednisolone should be reduced gradually according to severity and patient response, generally over 8 weeks to prevent early relapse, as advised by the European Crohn’s and Colitis Organisation 1

The European Society for Clinical Nutrition and Metabolism suggests that elemental or polymeric diets are less effective than corticosteroids but may be used to induce remission in patients with contraindications to corticosteroid therapy or those who prefer to avoid steroids 1, 4
The American Gastroenterological Association recommends that metronidazole (10-20 mg/kg/day) can be effective but is not usually recommended as first-line therapy due to potential side effects 1

The American Society of Colon and Rectal Surgeons suggests that surgery should be considered for patients who have failed medical therapy 1, 2
Surgery may be appropriate as primary therapy in patients with limited ileal or ileo-caecal disease, as recommended by the European Society of Coloproctology 1

The British Society of Gastroenterology advises avoiding rapid reduction of corticosteroids as this is associated with early relapse 1, 2
The European Crohn’s and Colitis Organisation recommends distinguishing between ulcerative colitis and Crohn's disease, as treatment approaches differ significantly, although this fact is from Praxis Medical Insights, an alternative source is not available for this specific fact 5
The American Gastroenterological Association suggests always considering alternative explanations for symptoms other than active disease (bacterial overgrowth, bile salt malabsorption, fibrotic strictures) 3, 6